4basebio Plc - Director's Dealing
03 Março 2025 - 1:37PM
UK Regulatory
4basebio Plc - Director's Dealing
PR Newswire
LONDON, United Kingdom, March 03
3
March 2025
4basebio
plc
(“4basebio”
or the "Company")
Director’s
Dealing
3
March 2025 – 4basebio PLC (AIM: 4BB),
which develops and commercialises the large-scale manufacture of
synthetic DNA as well as nanoparticle delivery solutions,
announces that
it was informed on
28 February 2025 by Dr. Amy Walker, COO of the Company, that on the same
day, she acquired ordinary shares in the Company through the
market, at a price of 1,120p as
follows:
|
Name |
Numberof
Shares Acquired |
Shareholding
Prior to the
Acquisition |
Shareholding
Following the
Acquisition |
Enlarged Shareholding as a
Percentage of Issued Share
Capital |
|
Dr. Amy
Walker |
1,151 |
42,865* |
44,016 |
0.28% |
* Dr Walker’s shareholding
includes 2,818 ordinary shares that had been omitted in the
announcement of 8 August
2024
The issued share capital
of the Company comprises 15,477,395 ordinary
shares.
This announcement contains inside information for the
purposes of Article 7 of EU Regulation 596/2014 as amended by
regulation 11 of the market abuse (amendment) (EU Exit) regulations
2019/310.
Enquiries
|
4basebio
PLC
Dr. Heikki
Lanckriet
|
+44 (0)1223 967
943
|
|
Nominated
Adviser
Cairn Financial
Advisers LLP
Jo Turner / Sandy Jamieson
/ Ed Downes
|
+44 (0)20 7213
0880
|
|
Joint Corporate
Broker
RBC Capital
Markets
Rupert Walford / Kathryn
Deegan
|
+44 (0)20 7653
4000
|
|
Joint Corporate
Broker
Cavendish Capital
Markets Limited
Geoff Nash / Nigel
Birks
|
+44 (0)20 7220
0500
|
Notes to
Editors
About
4basebio
4basebio (AIM: 4BB) is an
innovation driven life biotechnology company focused on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high-performance synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company’s objective is to become a market leader in the manufacture
and supply of high-quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients.
|
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No.
596/2014 |
|
1 |
Details of the person discharging managerial
responsibilities/person closely
associated |
|
a. |
Name |
Amy
Walker |
|
2 |
Reason for
notification |
|
|
a. |
Position/Status |
COO |
|
b. |
Initial
notification/Amendment |
Initial
Notification |
|
3 |
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor |
|
a. |
Name |
4basebio
plc |
|
b. |
LEI |
213800E2DX9EAIUNCB30 |
|
4 |
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have been
conducted |
|
a. |
Description of the financial instrument, type of
instrument
Identification Code |
Ordinary
Shares
ISIN:
GB00BMCLYF79 |
|
b. |
Nature of the
transaction |
Acquisition of ordinary
shares |
|
|
|
|
Price(s) per share
(p) |
Volume(s) |
|
|
1,120p |
1,151 |
|
|
|
|
d. |
Aggregated
information
|
-
1,151
-
1,120 pence per
share
|
|
e. |
Date of the
transaction |
28/02/2025 |
|
f. |
Place of the
transaction |
London Stock Exchange,
AIM |
4basebio (LSE:4BB)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
4basebio (LSE:4BB)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
